Q-omics provides the consensus-scored WFDC21P profile across patient tissues and cancer cell-line models. WFDC21P expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, WFDC21P is differentially expressed in 11, with the highest sampling consensus in HNSC. Additionally, WFDC21P RNA expression shows 14,172 significant protein co-abundance associations, with the highest sampling consensus in BRCA. Together, these results highlight HNSC, and BRCA as cancer lineages where WFDC21P shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for WFDC21P — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes WFDC21P survival associations across molecular data types. WFDC21P RNA expression shows survival associations in the most cancer types (23). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible WFDC21P RNA expression–survival associations across cancer types. High WFDC21P expression shows unfavorable associations in BRCA, UCS and UVM, but favorable associations in HNSC, CESC and KIRP. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for WFDC21P RNA expression.
This table summarizes WFDC21P tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for WFDC21P. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. WFDC21P shows lower tumor expression in HNSC and KICH and higher tumor expression in KIRP, BRCA, LIHC and COAD. The HNSC box plot shows higher WFDC21P RNA expression in normal versus tumor tissue (log2 FC = −2.541, t-test p < 0.001).
This table shows molecular features associated with WFDC21P in patient tissues and cancer cell lines. In patient samples, WFDC21P shows the broadest associations at the RNA and protein expression levels, with BRCA recurring as the lineage with the largest associated feature set.
